Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accretion PharmaceuticalsNSE:ACCPL +2.56%21 Piotroski F-Score is 5 as of Aug. 19, 2026, which is at its 10-year median of 5.00. GuruFocus rates NSE:ACCPL with a GF Score™ of 21/100. The stock has 6 warning signs investors should review. Among 979 Drug Manufacturers companies, Accretion Pharmaceuticals ranks better than 61.08% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Accretion Pharmaceuticals has an F-score of 5 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Accretion Pharmaceuticals's Piotroski F-Score or its related term are showing as below:
NSE:ACCPL'
s Piotroski F-Score Range Over the Past 10 Years
Min: 5 Med: 5 Max: 5
Current: 5
During the past 5 years, the highest Piotroski F-Score of Accretion Pharmaceuticals was 5. The lowest was 5. And the median was 5.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Accretion Pharmaceuticals Piotroski F-Score Related Terms
Accretion Pharmaceuticals Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ACCPL vs LLY, JNJ, ABBV: Piotroski F-Score Comparison
For the Drug Manufacturers - General subindustry, Accretion Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Pharmaceuticals Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Pharmaceuticals's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Accretion Pharmaceuticals's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Accretion Pharmaceuticals's current Net Income (TTM) was 96.7.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Accretion Pharmaceuticals's current Cash Flow from Operations (TTM) was -145.3.
==> Negative ==> Score 0.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Accretion Pharmaceuticals's return on assets of this year was 0.24244879. Accretion Pharmaceuticals's return on assets of last year was 0.25118224.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Accretion Pharmaceuticals's gearing of this year was 0.01479988. Accretion Pharmaceuticals's gearing of last year was 0.03489514.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Accretion Pharmaceuticals's current ratio of this year was 2.89844125. Accretion Pharmaceuticals's current ratio of last year was 1.44000827.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Accretion Pharmaceuticals's number of shares in issue this year was 10.704. Accretion Pharmaceuticals's number of shares in issue last year was 11.116.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Accretion Pharmaceuticals's gross margin of this year was 0.27306777. Accretion Pharmaceuticals's gross margin of last year was 0.30442065.
==> Last year's gross margin is higher ==> Score 0.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Accretion Pharmaceuticals's asset turnover of this year was 2.2477379. Accretion Pharmaceuticals's asset turnover of last year was 2.12142231.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
0
+
0
+
0
+
1
+
1
+
1
+
0
+
1
=
5
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Accretion Pharmaceuticals has an F-score of 5 indicating the company's financial situation is typical for a stable company.
Accretion Pharmaceuticals (NSE:ACCPL) has a Piotroski F-Score of 5 as of Aug. 19, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Accretion Pharmaceuticals and its competitors. This is near median its historical median of 5.00. Over the past decade, Accretion Pharmaceuticals' Piotroski F-Score has ranged from 5.00 to 5.00. According to the industry distribution chart, Accretion Pharmaceuticals ranks #381 out of 979 companies in the Drug Manufacturers industry, placing it in the top 38.9%.
Is Accretion Pharmaceuticals' Piotroski F-Score too high?
Accretion Pharmaceuticals' current Piotroski F-Score of 5 is near median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 5.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Accretion Pharmaceuticals' value of 5 is 0% at this industry median. Based on the distribution chart, Accretion Pharmaceuticals ranks #381 out of 979 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Accretion Pharmaceuticals has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' Piotroski F-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Accretion Pharmaceuticals ranks #381 out of 979 companies for Piotroski F-Score. This puts Accretion Pharmaceuticals in the upper half of its industry. The industry median Piotroski F-Score is 5.00. Accretion Pharmaceuticals' value of 5 is 0% at this benchmark. Historically, Accretion Pharmaceuticals' own Piotroski F-Score has ranged from 5.00 to 5.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Accretion Pharmaceuticals has consistently been at the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accretion Pharmaceuticals's current Piotroski F-Score of 5 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Accretion Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Pharmaceuticals's current Piotroski F-Score is 5, which is near median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current Piotroski F-Score of 5. The current Piotroski F-Score is 5, which is near median its 10-year median of 5.00 and 0% at the Drug Manufacturers industry median of 5.00. Accretion Pharmaceuticals' overall GF Score™ is 21/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current Piotroski F-Score is 5 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
21GF Score
Get the complete analysis for NSE:ACCPL
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ACCPL has been successfully added to your 
